Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.
|
|
Reuters NewMedia, Inc.; Tuesday June 30, 7:33 pm EST
Vertex said that six of nine patients with HIV had less than five viral copies per milliliter (mL) of plasma and that of the other three patients completing 48 weeks, two had less than 50 copies/mL and one had less than 500 copies/mL. Agenerase was discovered by Vertex, which licensed the compound to Glaxo Wellcome (quote from Yahoo! UK & Ireland: GLXO.L).
Ziagen was discovered and is being developed by Glaxo Wellcome. Vertex said these results were presented at the 12th World AIDS Conference in Geneva.
"The reductions in virus among patients in this study...were profound and appear to be durable," said Lynn Smiley, vice president of Antiviral Clinical Research at Glaxo Wellcome, in a statement.
"While this study is small and far from conclusive, the results appear to support the antiviral potency of both Ziagen and Agenerase, and provides clinical support for preliminary laboratory data which demonstrate an in vitro synergy between the two drugs," she said.
Ziagen and Agenerase are in phase III clinical development at Glaxo Wellcome as treatments for HIV and AIDS.
980630
RE980619
Copyright © 1998 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .